The aim of this study was to investigate the relationship between type II diabetes mellitus (T2DM) and ALS incidence using the National Health Insurance Research Database and Serious Disabling Disease database of Taiwan.
This was a population-based cohort study. The index date was the date of the first T2DM diagnosis + 365 days. We included T2DM patients diagnosis between 2000 and 2013 (n = 2,135,427). These patients were matched by sex, age, urbanization, and insurance premium at a ratio of 1:1 to include patients without diabetes mellitus. Competing risk-adjusted Cox regression analysis was performed to investigate the association between T2DM and the incidence of ALS.
In the patients not stratified by age, T2DM was not associated with the incidence of ALS after controlling for confounding factors. The interaction test of age subgroup (< 55 and ≥ 55 years) and T2DM on ALS risk was significance (p < 0.001). Subgroup analysis showed that T2DM was negatively associated with ALS in patients whose age at the first T2DM diagnosis was ≥ 55 years. Among T2DM patients, T2DM combined with hypertension was negatively associated with ALS among patients whose age at the first T2DM diagnosis was ≥ 55 years. Among T2DM patients, T2DM combined with hyperlipidemia was positively associated with ALS among patients whose age at the first T2DM diagnosis was < 55 years.
The late-onset of T2DM may exert negative association with ALS, especially when combined with hypertension. The early-onset of T2DM may exert positive association with ALS, especially when combined with hyperlipidemia.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Tsai CP, Wang KC, Hwang CS, Lee IT, Lee CT (2015) Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999–2008. J Formos Med Assoc 114(7):612–619. https://doi.org/10.1016/j.jfma.2013.01.008
Holecek V, Rokyta R (2018) Possible etiology and treatment of amyotrophic lateral sclerosis. Neuro Endocrinol Lett 38(8):528–531
Hollinger SK, Okosun IS, Mitchell CS (2016) Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol 7:47. https://doi.org/10.3389/fneur.2016.00047
Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258(4):613–617. https://doi.org/10.1007/s00415-010-5805-z
Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE (2010) ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 17(5):733–739. https://doi.org/10.1111/j.1468-1331.2009.02923.x
Gallo V, Wark PA, Jenab M, Pearce N, Brayne C, Vermeulen R, Andersen PM, Hallmans G, Kyrozis A, Vanacore N, Vahdaninia M, Grote V, Kaaks R, Mattiello A, Bueno-de-Mesquita HB, Peeters PH, Travis RC, Petersson J, Hansson O, Arriola L, Jimenez-Martin JM, Tjonneland A, Halkjaer J, Agnoli C, Sacerdote C, Bonet C, Trichopoulou A, Gavrila D, Overvad K, Weiderpass E, Palli D, Quiros JR, Tumino R, Khaw KT, Wareham N, Barricante-Gurrea A, Fedirko V, Ferrari P, Clavel-Chapelon F, Boutron-Ruault MC, Boeing H, Vigl M, Middleton L, Riboli E, Vineis P (2013) Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 80(9):829–838. https://doi.org/10.1212/WNL.0b013e3182840689
Ji J, Sundquist J, Sundquist K (2016) Association of alcohol use disorders with amyotrophic lateral sclerosis: a Swedish National Cohort Study. Eur J Neurol 23(2):270–275. https://doi.org/10.1111/ene.12667
Jawaid A, Khan R, Polymenidou M, Schulz PE (2018) Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol Neurodegener 13(1):63. https://doi.org/10.1186/s13024-018-0294-0
D'Ovidio F, d'Errico A, Carna P, Calvo A, Costa G, Chio A (2018) The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol 25(1):164–170. https://doi.org/10.1111/ene.13465
Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72(8):905–911. https://doi.org/10.1001/jamaneurol.2015.0910
Mariosa D, Kamel F, Bellocco R, Ye W, Fang F (2015) Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 22(11):1436–1442. https://doi.org/10.1111/ene.12632
Turner MR, Goldacre R, Talbot K, Goldacre MJ (2016) Psychiatric disorders prior to amyotrophic lateral sclerosis. Ann Neurol 80(6):935–938. https://doi.org/10.1002/ana.24801
Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, Van den Berg LH (2011) Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 82(6):638–642. https://doi.org/10.1136/jnnp.2010.236752
Hardiman O (2011) Amyotrophic lateral sclerosis and vascular risk: a metabolic conundrum. J Neurol Neurosurg Psychiatry 82(6):591. https://doi.org/10.1136/jnnp.2011.241539
Turner MR, Goldacre R, Talbot K, Goldacre MJ (2015) Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 87(3):244–246. https://doi.org/10.1136/jnnp-2015-311157
Logroscino G, Ludolph A (2014) Amyotrophic lateral sclerosis: new ideas from cancer. Lancet Neurol 13(11):1067–1068. https://doi.org/10.1016/S1474-4422(14)70177-2
Gibson SB, Abbott D, Farnham JM, Thai KK, McLean H, Figueroa KP, Bromberg MB, Pulst SM, Cannon-Albright L (2016) Population-based risks for cancer in patients with ALS. Neurology 87(3):289–294. https://doi.org/10.1212/WNL.0000000000002757
Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ (2013) Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology 81(14):1222–1225
Paganoni S, Hyman T, Shui A, Allred P, Harms M, Liu J, Maragakis N, Schoenfeld D, Yu H, Atassi N (2015) Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve 52(3):339–343
Sun Y, Lu CJ, Chen RC, Hou WH, Li CY (2015) Risk of amyotrophic lateral sclerosis in patients with diabetes: a nationwide population-based cohort study. J Epidemiol 25(6):445–451. https://doi.org/10.2188/jea.JE20140176
Freedman DM, Wu J, Daugherty SE, Kuncl RW, Enewold LR, Pfeiffer RM (2014) The risk of amyotrophic lateral sclerosis after cancer in US elderly adults: a population-based prospective study. Int J Cancer 135(7):1745–1750. https://doi.org/10.1002/ijc.28795
National Health Research Institute (1998) Introduction to the national health insurance research database (NHIRD). Taiwan. http://nhird.nhri.org.tw/en/. Retrieved May 2019
Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY (2005) Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 104(3):157–163
Vandoorne T, De Bock K, Van Den Bosch L (2018) Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol 135(4):489–509. https://doi.org/10.1007/s00401-018-1835-x
Dupuis L, Pradat PF, Ludolph AC, Loeffler JP (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10(1):75–82. https://doi.org/10.1016/s1474-4422(10)70224-6
Mitchell CS, Hollinger SK, Goswami SD, Polak MA, Lee RH, Glass JD (2015) Antecedent disease is less prevalent in amyotrophic lateral sclerosis. Neurodegener Dis 15(2):109–113. https://doi.org/10.1159/000369812
Kaur P, Muthuraman A, Kaur M (2015) The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci 6(4):508–521. https://doi.org/10.1021/cn500363g
Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi Lee C (2015) Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 72(1):40–48. https://doi.org/10.1001/jamaneurol.2014.3367
Mariosa D, Hammar N, Malmstrom H, Ingre C, Jungner I, Ye W, Fang F, Walldius G (2017) Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol 81(5):718–728. https://doi.org/10.1002/ana.24936
Taylan E, Tuncel EP (2016) Distribution of LDL subgroups in patients with hyperlipidemia. Turk J Med Sci 46(2):374–380. https://doi.org/10.3906/sag-1410-40
Dr. Charles Tzu-Chi Lee had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This study was supported by grants from the Taiwan Motor Neuron Disease Association (TMND). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflict of interest
All the authors declare that they have no conflicts of interest.
About this article
Cite this article
Tsai, CP., Lee, J.KW. & Lee, C.TC. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol 266, 2233–2243 (2019). https://doi.org/10.1007/s00415-019-09405-x
- Amyotrophic lateral sclerosis
- National Health Insurance Database
- Serious Disabling Disease Database
- Diabetes mellitus
- Cohort study